2019
Cost‐Effectiveness of Diet and Exercise for Overweight and Obese Patients With Knee Osteoarthritis
Losina E, Smith KC, Paltiel AD, Collins JE, Suter LG, Hunter DJ, Katz JN, Messier SP. Cost‐Effectiveness of Diet and Exercise for Overweight and Obese Patients With Knee Osteoarthritis. Arthritis Care & Research 2019, 71: 855-864. PMID: 30055077, PMCID: PMC6349519, DOI: 10.1002/acr.23716.Peer-Reviewed Original ResearchMeSH KeywordsAgedCaloric RestrictionComparative Effectiveness ResearchComputer SimulationCost-Benefit AnalysisExerciseFemaleHealth Care CostsHealthy LifestyleHumansMaleMiddle AgedModels, EconomicMonte Carlo MethodObesityOsteoarthritis, KneeQuality of LifeQuality-Adjusted Life YearsRisk Reduction BehaviorTime FactorsTreatment OutcomeWeight LossConceptsIncremental cost-effectiveness ratioProbabilistic sensitivity analysesKnee osteoarthritisObese patientsIntensive dietSocietal perspectiveHealth care sector perspectiveLifetime costsOsteoarthritis Policy ModelCost-effectiveness ratioIDEA trialPain reductionUsual careExercise programArthritis trialsTreatment strategiesLifetime horizonClinical practicePatientsOsteoarthritisOverweightQALYHealth care sectorWeight reductionDiet
2017
The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States
Borre ED, Hyle EP, Paltiel AD, Neilan AM, Sax PE, Freedberg KA, Weinstein MC, Walensky RP. The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States. The Journal Of Infectious Diseases 2017, 216: 798-807. PMID: 29029344, PMCID: PMC5853503, DOI: 10.1093/infdis/jix349.Peer-Reviewed Original ResearchConceptsNational HIV/AIDS StrategyIncremental cost-effectiveness ratioHuman immunodeficiency virusCost-effectiveness ratioUS National HIV/AIDS StrategyHIV/AIDS StrategyAntiretroviral therapy costsSubstantial clinical benefitHigh HIV prevalenceGeneral US populationYears of lifeVirologic suppressionViral suppressionClinical outcomesAdherence interventionsClinical benefitHIV prevalenceHIV transmissionImmunodeficiency virusMSM populationAIDS StrategyTherapy costsTreatment targetsUS populationBlack men
2013
Placing a Price on Medical Device Innovation: The Example of Total Knee Arthroplasty
Suter LG, Paltiel AD, Rome BN, Solomon DH, Thornhill TS, Abrams SK, Katz JN, Losina E. Placing a Price on Medical Device Innovation: The Example of Total Knee Arthroplasty. PLOS ONE 2013, 8: e62709. PMID: 23671626, PMCID: PMC3646021, DOI: 10.1371/journal.pone.0062709.Peer-Reviewed Original ResearchDisease-modifying drugs for knee osteoarthritis: can they be cost-effective?
Losina E, Daigle ME, Suter LG, Hunter DJ, Solomon DH, Walensky RP, Jordan JM, Burbine SA, Paltiel AD, Katz JN. Disease-modifying drugs for knee osteoarthritis: can they be cost-effective? Osteoarthritis And Cartilage 2013, 21: 655-667. PMID: 23380251, PMCID: PMC3670115, DOI: 10.1016/j.joca.2013.01.016.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioQuality-adjusted life yearsTotal knee replacementPain reliefMajor toxicityRevision total knee replacementCare sequenceConservative pain managementGuideline-concordant careKnee OA treatmentQuality-adjusted life expectancyOsteoarthritis Policy ModelCost-effectiveness ratioCorticosteroid injectionKnee OAKnee osteoarthritisPain managementOsteoarthritis drugsKnee replacementDMOADsOA treatmentLife yearsProgressionLife expectancyRelief
2010
Routine HIV Screening in France: Clinical Impact and Cost-Effectiveness
Yazdanpanah Y, Sloan CE, Charlois-Ou C, Le Vu S, Semaille C, Costagliola D, Pillonel J, Poullié AI, Scemama O, Deuffic-Burban S, Losina E, Walensky RP, Freedberg KA, Paltiel AD. Routine HIV Screening in France: Clinical Impact and Cost-Effectiveness. PLOS ONE 2010, 5: e13132. PMID: 20976112, PMCID: PMC2956760, DOI: 10.1371/journal.pone.0013132.Peer-Reviewed Original ResearchConceptsQuality-adjusted life monthsCost-effectiveness ratioQuality-adjusted life yearsGeneral populationRoutine HIVHIV prevalenceFrequent screeningLife expectancyAnnual HIV incidenceRoutine HIV screeningUndiagnosed HIV prevalenceHigh-risk groupHIV testing behaviorsInjection drug usersFrench general populationEpidemiology of infectionHIV screeningVoluntary HIVHIV infectionHIV testingAnnual screeningHIV incidenceMean ageHIV screenClinical impact
2005
Cost-Effectiveness of Enfuvirtide in Treatment-Experienced Patients With Advanced HIV Disease
Sax PE, Losina E, Weinstein MC, Paltiel AD, Goldie SJ, Muccio TM, Kimmel AD, Zhang H, Freedberg KA, Walensky RP. Cost-Effectiveness of Enfuvirtide in Treatment-Experienced Patients With Advanced HIV Disease. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2005, 39: 69-77. PMID: 15851916, DOI: 10.1097/01.qai.0000160406.08924.a2.Peer-Reviewed Original Research
2004
Quality of life after aortic valve replacement with tissue and mechanical implants
Sedrakyan A, Hebert P, Vaccarino V, Paltiel AD, Elefteriades JA, Mattera J, Lin Z, Roumanis SA, Krumholz HM. Quality of life after aortic valve replacement with tissue and mechanical implants. Journal Of Thoracic And Cardiovascular Surgery 2004, 128: 266-272. PMID: 15282464, DOI: 10.1016/j.jtcvs.2003.12.014.Peer-Reviewed Original ResearchMeSH KeywordsAgedAortic ValveFemaleHeart Valve ProsthesisHumansMaleMiddle AgedProspective StudiesQuality of LifeConceptsAortic valve replacementQuality of lifeMechanical valve implantsMechanical valve recipientsValve replacementValve recipientsLife scoresValve implantsTissue valvesMechanical valvesMedical Outcomes Trust Short FormPopulation normsYale-New Haven HospitalMechanical valve replacementRate of complicationsUS population normsTissue valve replacementPrognostic factorsRole limitationsOnly significant differenceHealth SurveyAnalysis of covarianceBaseline qualityMean qualityPatientsAssociation between preference-based health-related quality of life and asthma severity
Moy ML, Fuhlbrigge AL, Blumenschein K, Chapman RH, Zillich AJ, Kuntz KM, Paltiel AD, Kitch BT, Weiss ST, Neumann PJ. Association between preference-based health-related quality of life and asthma severity. Annals Of Allergy Asthma & Immunology 2004, 92: 329-334. PMID: 15049396, DOI: 10.1016/s1081-1206(10)61570-0.Peer-Reviewed Original ResearchConceptsPreference-based measuresHealth Utilities Index 3Standard gambleAsthma Symptom Utility IndexTime tradeoffPreference-based health-related qualityResource allocation decisionsHealth statesCost-effectiveness analysisStrength of preferenceSubject's health stateAllocation decisionsAsthma severityHealth-related qualityValues peoplePreference scoresPreference instrumentSymptom frequencyRating ScaleUtility indexAirway obstructionLung functionHUI3 scoresHealth improvementPreferences
2003
Age does not limit quality of life improvement in cardiac valve surgery
Sedrakyan A, Vaccarino V, Paltiel AD, Elefteriades JA, Mattera JA, Roumanis SA, Lin Z, Krumholz HM. Age does not limit quality of life improvement in cardiac valve surgery. Journal Of The American College Of Cardiology 2003, 42: 1208-1214. PMID: 14522482, DOI: 10.1016/s0735-1097(03)00949-5.Peer-Reviewed Original ResearchConceptsMental component summaryQuality of lifeCardiac valve surgeryPhysical component summaryValve surgeryAssociation of ageValve proceduresComponent summarySF-36PCS scoresMedical Outcomes Trust Short FormPatients' QOLMitral valve proceduresAortic valve proceduresOlder patientsAortic patientsMCS scoresMitral patientsQOL benefitsHealth SurveyPatientsSurgeryStatistical significanceAgeMultiple regression analysis
2002
Prevention of Human Immunodeficiency Virus—Related Opportunistic Infections in France: A Cost-Effectiveness Analysis
Yazdanpanah Y, Goldie S, Paltiel A, Losina E, Coudeville L, Weinstein M, Gerard Y, Kimmel A, Zhang H, Salamon R, Mouton Y, Freedberg K. Prevention of Human Immunodeficiency Virus—Related Opportunistic Infections in France: A Cost-Effectiveness Analysis. Clinical Infectious Diseases 2002, 36: 86-96. PMID: 12491207, DOI: 10.1086/344902.Peer-Reviewed Original ResearchConceptsCost-effectiveness ratioTMP-SMZAntiretroviral therapyHIV diseaseOpportunistic infectionsHuman immunodeficiency virus (HIV) diseaseMycobacterium avium complex bacteremiaIncremental cost-effectiveness ratioPerson lifetime costsActive antiretroviral therapyEra of HAARTPneumocystis carinii pneumoniaHuman immunodeficiency virusQuality-adjusted life expectancyCost-effectiveness analysisOral ganciclovirCytomegalovirus infectionToxoplasmic encephalitisCarinii pneumoniaImmunodeficiency virusTherapeutic optionsClinical impactFrench patientsProphylaxisInfection
2001
Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: Results from the Asthma Policy Model
Paltiel AD, Fuhlbrigge AL, Kitch BT, Liljas B, Weiss ST, Neumann PJ, Kuntz KM. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: Results from the Asthma Policy Model. Journal Of Allergy And Clinical Immunology 2001, 108: 39-in4. PMID: 11447380, DOI: 10.1067/mai.2001.116289.Peer-Reviewed Original ResearchConceptsSymptom-free daysCorticosteroid therapyAcute exacerbationModerate asthmaHealth-related qualityPopulation of patientsCost-effectiveness findingsHealth care costsCost-effectiveness analysisTotal health costsAdult asthmaObservational cohortRandomized trialsPatient preferencesPatient surveyClinical impactCorticosteroidsSide effectsCare costsDrug efficacyNatural historyAsthmaIncremental costTherapyMild